# The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19

> **NCT04891302** · PHASE2 · COMPLETED · sponsor: **Bukwang Pharmaceutical** · enrollment: 104 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Clevudine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04891302
- **Lead sponsor:** Bukwang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-19
- **Primary completion:** 2021-07-05
- **Final completion:** 2021-07-08
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2022-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04891302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04891302, "The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04891302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*